Equities analysts forecast that Teligent Inc (NASDAQ:TLGT) will post earnings of ($0.11) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Teligent’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.13). Teligent posted earnings of $0.01 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 1,200%. The company is scheduled to report its next earnings report on Tuesday, March 6th.
On average, analysts expect that Teligent will report full year earnings of ($0.14) per share for the current year, with EPS estimates ranging from ($0.15) to ($0.11). For the next fiscal year, analysts forecast that the business will post earnings of $0.06 per share, with EPS estimates ranging from ($0.06) to $0.15. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Teligent.
Teligent (NASDAQ:TLGT) last posted its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.07). The company had revenue of $13.65 million during the quarter, compared to the consensus estimate of $19.12 million. Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The business’s quarterly revenue was down 15.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.01 earnings per share.
Shares of Teligent (NASDAQ:TLGT) traded down $0.03 on Wednesday, hitting $2.99. The stock had a trading volume of 18,975 shares, compared to its average volume of 516,861. The firm has a market capitalization of $152.19, a price-to-earnings ratio of -12.91, a price-to-earnings-growth ratio of 57.00 and a beta of 1.07. The company has a debt-to-equity ratio of 2.23, a current ratio of 3.28 and a quick ratio of 2.71. Teligent has a 52 week low of $2.75 and a 52 week high of $9.54.
Large investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC grew its holdings in Teligent by 16.1% during the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock worth $214,000 after acquiring an additional 3,234 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Teligent by 26.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 74,300 shares of the company’s stock worth $270,000 after purchasing an additional 15,400 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Teligent by 85.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 34,549 shares of the company’s stock worth $316,000 after purchasing an additional 15,933 shares in the last quarter. Wells Fargo & Company MN increased its stake in Teligent by 52.4% in the 3rd quarter. Wells Fargo & Company MN now owns 49,264 shares of the company’s stock worth $331,000 after purchasing an additional 16,937 shares in the last quarter. Finally, New Jersey Better Educational Savings Trust increased its stake in Teligent by 25.0% in the 3rd quarter. New Jersey Better Educational Savings Trust now owns 50,000 shares of the company’s stock worth $336,000 after purchasing an additional 10,000 shares in the last quarter. 72.11% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/07/zacks-analysts-expect-teligent-inc-tlgt-to-post-0-11-earnings-per-share.html.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.